Sending a patient home with their anti-cancer medication incurs some advantages and disadvantages; data supports the use of medically-integrated teams to overcome the potential downfalls of outpatient therapy including access issues and side effect management. NCODA agrees that the best site of care for a patient is with their oncologist and the multi-disciplinary team. Read […]

Natasha Khrystolubova is one of the lead author of the Journal of Oncology Pharmacy Practice article, Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. An NCODA practice working to make a difference in the pharmacy to positively impact patient care. Florida […]

FOR IMMEDIATE RELEASE March 15, 2019 NCODA Announces Dr. Mario Lacouture as Director of the Medical Advisory Board for Treatment Support Program Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA) Executive Council is pleased to announce that Mario Lacouture, M.D. will be joining the Treatment Support Program as Director of the Medical […]

Drug pricing, manufacturer rebates, and PBM transparency are all critical questions that are being asked of today’s insurers; unfortunately, this particular response from UHC might actually push patients away from the medically-integrated team and into their own specialty pharmacy system. NCODA supports efforts to enhance the continuity of care at the physician level where we […]

Mission Statement: Summit Cancer Centers mission is to maintain and increase high quality, lower cost cancer services, and to work at peak efficiency through owning, managing and operating comprehensive community cancer care facilities; and to offer patients throughout the Northwest a broad array of integrated, multidisciplinary cancer care services.  Locations: Spokane, Spokane Valley, Post Falls, Boise Practice Details: […]

NCODA is closely watching today’s hearing on the issue of drug pricing. We will see the CEOs from AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck & Co, Pfizer, and Sanofi (plus the head of J&J’s pharma division) debate drug prices with lawmakers at a time when major legislative reform seems to be looming. More

Mission Statement: Women & Infants Hospital, a teaching hospital of The Warren Alpert Medical School of Brown University, is committed to improving the health and well-being of women and infants and to providing our essential services regardless of ability to pay.

NCODA supports the principle that medications should improve the patient’s quality of life while simultaneously treating the disease. We will continue to follow these developments as our patient-centered approach reaches the heart of clinical trial design in the oncology space. Article here

Former NCODA Keynote Speaker Doug Collins (R-Ga.) reintroduced legislation that would increase transparency in drug pricing while lowering costs for patients. Updates on H.R. 1035 The Prescription Drug Pricing Transparency Act and H.R. 1034 The Phair Pricing Act can be found here at NCODA as we continue to advocate for cancer patients. Read More

Lawmakers are pushing forward legislation that would allow biosimilar and generic competition to enter the market sooner, suggesting that this change will drive down drug prices for US patients. Read more

Recent meta-analysis reveals low-dose aspirin may reduce the risk of certain cancers. Read more here:

Health insurer Anthem is launching its in-house pharmacy benefit manager IngenioRx nine months earlier than planned in the second quarter of 2019.  Anthem said Wednesday that it will exercise its rights to terminate its current PBM contract with Express Scripts on March 1 before it expires at the end of the year, due to Cigna […]